Actually Obleix is right n = 10 is quite low (although fine for...

Actually Obleix is right n = 10 is quite low (although fine for rare diseases). Even though it says statistically significant we will need to get way more data on who the patients where (m/f, age, progression of disease, amt of ARB, blood-drug levels etc.) before we can break out the champagne. Secondly, only seven of those qualified for final analysis.

It does help to say that with a small study, we will need more info as investors/doctors/patients/mgmt before we are confident of us shareholders getting some big pay days. De-risking this will include some form of licensing deal I would imagine.

That is why a Ph3 is needed next with a much larger pop. Else on just the Ph2 we could go straight to commercialization.

As a holder I am happy for the company and everyone involved. As an investor, I await more info and a ph3.